News Headlines

  1. Agilent Expands Oligonucleotide Manufacturing Capabilities With New Boulder Lab 10/5/2026

    Agilent Technologies Inc. (NYSE: A) today announced the addition of new laboratory space in Boulder, Colorado, to support the expansion of its oligonucleotide manufacturing capabilities. The facility is expected to support the development and scale-up of emerging manufacturing technologies for oligonucleotide therapeutics, initially focusing on enzymatic ligation.

  2. Flamma Acquires API Manufacturing Site In Padova, Italy 10/5/2026
  3. Psyence BioMed Partners With DEA-Registered Benuvia Operations To Establish U.S. Manufacture Of Pharmaceutical-Grade Ibogaine 10/5/2026

    Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research Corporation (“TIRC”), has entered into a manufacturing services agreement with Benuvia Operations, LLC (“Benuvia”) of Round Rock, Texas, establishing a manufacturing partnership for the planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient (“API”) under current Good Manufacturing Practice (“cGMP”) standards.

  4. Lonza And Asimov Collaborate To Advance In Vivo Lentiviral Vector Manufacturing 10/5/2026

    Lonza, the world's leading contract development and manufacturing organization (CDMO), and Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, announced today a strategic collaboration to advance lentiviral vector (LVV) manufacturing for emerging in vivo applications. 

  5. Genezen And InterAct Therapeutics Partner To Advance AAV8-Based Gene Therapy For Liver-Dominant Metastatic Breast Cancer 10/5/2026

    Genezen, a gene therapy contract development and manufacturing organization (CDMO), and InterAct Therapeutics, a gene therapy innovation organization with a proprietary platform that pinpoints cancer targets and powers anti-metastasis therapies to save lives, today announced a strategic manufacturing partnership to advance the clinical development of a therapy for breast cancer liver metastases (BCLM).

  6. Flamma Acquires API Manufacturing Site In Italy From Lundbeck 10/5/2026

    Flamma, a global Contract Development and Manufacturing Organization (CDMO) focused on small molecule APIs, peptides and advanced intermediates, today announced that it has entered into an agreement to acquire Lundbeck Pharmaceuticals Italy SpA (“LuPI”) from H. Lundbeck A/S (“Lundbeck”). The transaction is subject to customary closing conditions and is expected to close on January 1, 2027.

  7. Energenesis Biomedical And Yoo Young Pharm Sign MOU For ENERGI-F703DFU Development And Commercialization In Korea 10/5/2026

    Energenesis Biomedical Co., Ltd. (TWSE: 6657) today announced that it has signed a Memorandum of Understanding ("MOU") with Yoo Young Pharm. Co., Ltd. ("YYP"), a South Korea-based pharmaceutical company, to explore a collaboration for the development, registration, and commercialization of ENERGI-F703DFU in Korea.

  8. Bora Biologics And Protect Animal Health Enter Strategic, Long-Term Multi-Project Collaboration To Advance Antibody-Based Animal Health Products 10/4/2026

    Bora Biologics, a U.S.-anchored biologics contract development and manufacturing organization (CDMO) built for licensed supply, and Protect Animal Health, an animal health biotechnology company advancing antibody-based solutions for veterinary medicine, today announced a long-term, multi-project collaboration to support the development and manufacturing of Protect’s animal health product pipeline.

  9. CSL And Alentis Announce Global Partnership To Develop And Commercialise Lixudebart For Rare Kidney And Liver Diseases 10/4/2026

    CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases.

  10. AstraZeneca And Daiichi Sankyo Announce Clinical Collaboration With Summit Therapeutics To Evaluate Datroway In Combination With Ivonescimab Across Multiple Tumour Types 10/2/2026

    AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration agreement with Summit Therapeutics Inc. to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple tumour types including lung and breast cancers.